SUTRO BIOPHARMA
NASDAQ: STRO (Sutro Biopharma, Inc.)
Last update: 1 hour ago16.86
-0.97 (-5.44%)
| Previous Close | 17.83 |
| Volume | 942,335 |
| Price / Earnings (Forward) | 10.03 |
| Price / Sales | 4.31 |
| Price / Book | 2.11 |
| 52 Weeks Range |
| Operating Margin (TTM) | -272.84% |
| Diluted EPS (TTM) | -2.92 |
| Quarterly Revenue Growth (YOY) | 33.80% |
| Total Debt/Equity (MRQ) | 51.91% |
| Current Ratio (MRQ) | 2.16 |
| Operating Cash Flow (TTM) | -194.68 M |
| Levered Free Cash Flow (TTM) | -81.28 M |
| Return on Assets (TTM) | -39.55% |
| Return on Equity (TTM) | -679.15% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Sutro Biopharma, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | -1.67 |
|
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 4.58% |
| % Held by Institutions | 75.70% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Perceptive Advisors Llc | 30 Jun 2026 | 1,304,846 |
| Bvf Inc/Il | 30 Jun 2026 | 1,251,788 |
| Affinity Asset Advisors, Llc | 30 Jun 2026 | 1,172,487 |
| Samsara Biocapital, Llc | 30 Jun 2026 | 1,062,872 |
| Kynam Capital Management, Lp | 30 Jun 2026 | 872,558 |
| Orbimed Advisors Llc | 30 Jun 2026 | 743,944 |
| Balyasny Asset Management L.P. | 30 Jun 2026 | 711,162 |
| Eventide Asset Management, Llc | 30 Jun 2026 | 585,262 |
| Velan Capital Investment Management Lp | 30 Jun 2026 | 512,160 |
| Woodline Partners Lp | 30 Jun 2026 | 458,029 |
| Adar1 Capital Management, Llc | 30 Jun 2026 | 404,014 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |